Journal
LUNG CANCER
Volume 183, Issue -, Pages -Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2023.107314
Keywords
Neoadjuvant; Immunotherapy; NSCLC; Biomarker; Chemotherapy
Categories
Ask authors/readers for more resources
Only a minority of lung cancers are resectable at diagnosis, highlighting the need for new approaches to improve cure rates. Checkpoint inhibitor immunotherapy has shown promising results in advanced lung cancer and is being increasingly used in the neoadjuvant setting, but questions remain regarding optimal duration, biomarkers, response assessment, and combination with other therapies.
Only a minority of lung cancers are resectable at diagnosis, and many of these will eventually relapse. Adjuvant chemotherapy in this setting has a modest survival advantage, and there is significant need for new approaches to improve cure rates. Checkpoint inhibitor immunotherapy has transformed the prognosis for advanced lung cancer, and is increasingly being used in the neoadjuvant setting alone, or in combination with cytotoxic chemotherapy. While this has demonstrated convincing improvements in event-free survival and pathologic response, questions remain over optimal duration of therapy, predictive and prognostic biomarkers, response assessment and combination with other modalities. In addition, these results must be considered in the context of recent positive studies of adjuvant immunotherapy. Here, we summarise preclinical context and clinical trials in this space, discuss areas of controversy and pitfalls, and consider future challenges.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available